Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | GLA | P06280 | 3/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | GAA | P10253 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.52 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.52 |
| ▸ | CASP6 | P55212 | 1/20 | 0.48 |
| ▸ | HTR3A | P46098 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4944778 | 0.86 | KMT2A (0.44) | KMT2AALDH1A1MAPTHPGDGLA | |
| SCHEMBL244868 | 0.77 | KMT2A (0.59) | KMT2AALDH1A1MAPTHPGDGLA | |
| SCHEMBL29911341 | 0.77 | KMT2A (0.59) | KMT2AALDH1A1MAPTHPGDGLA | |
| SCHEMBL29454362 | 0.77 | TLR8 (0.57) | KMT2AALDH1A1MAPTHPGDGLA | |
| SCHEMBL359102 | 0.77 | TLR8 (0.57) | KMT2AALDH1A1MAPTHPGDGLA | |
| Hydrochloric Acid SCHEMBL27365120 | 0.76 | TLR8 (0.55) | KMT2AALDH1A1MAPTHPGDGLA | |
| SCHEMBL17993629 | 0.76 | KMT2A (0.57) | KMT2AALDH1A1MAPTHPGDGLA | |
| SCHEMBL31278632 | 0.76 | KMT2A (0.57) | KMT2AALDH1A1MAPTHPGDGLA | |
| Acridine SCHEMBL10827474 | 0.75 | ALDH1A1 (0.75) | KMT2AALDH1A1MAPTHPGDGLA | |
| SCHEMBL3300463 | 0.74 | TLR8 (0.53) | KMT2AALDH1A1MAPTHPGDGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111909087-A | Preparation method of chiral amino chloroquinoline | 珠海润都制药股份有限公司 | 2020-11-10 | — | — | CN | claimed |
| US-8394828-B2 | Quinoline-derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-12 | — | — | US | claimed |
| EP-1603883-B1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2012-03-28 | — | — | EP | claimed |
| US-20080300236-A1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | CODD ELLEN | 2008-12-04 | — | — | US | claimed |
| EP-1603883-A2 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-12-14 | — | — | EP | claimed |
| US-20040192728-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-09-30 | — | — | US | claimed |
| WO-2004069792-A2 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (US) | 2004-08-19 | — | — | WO | claimed |
| US-20250090540-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-03-20 | — | — | US | disclosed |
| CN-119524878-A | Disulfide vacancy SV-Bi2S3/SV-ZnIn2S4 heterojunction photocatalyst and preparation method and application thereof | 华东师范大学 | 2025-02-28 | — | — | CN | disclosed |
| CN-119264200-A | Galactose masking aminoquinoline compound and application thereof | 厦门大学 | 2025-01-07 | — | — | CN | disclosed |
| EP-4399196-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-118201896-A | PI 3K-alpha inhibitors and methods of use thereof | 传达治疗有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-117504916-A | BN-g-C for degrading chloroquine phosphate 3 N 4 /Cs 3 Bi 2 Br 9 Composite photocatalyst and synthesis method thereof | 华东师范大学 | 2024-02-06 | — | — | CN | disclosed |
| US-20050054640-A1 | 1-Amino 1H-imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-03-10 | — | — | US | disclosed |
| US-20040192728-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-09-30 | — | — | US | disclosed |
| WO-2004080398-A2 | 1-AMINO 1H-IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-09-23 | — | — | WO | disclosed |
| US-20040176367-A1 | 1-Amino 1H-imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-09-09 | — | — | US | disclosed |
| WO-2004069792-A2 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (US) | 2004-08-19 | — | — | WO | disclosed |
| CN-1063748-C | Naphthalene derivatives, process for preparation thereof, and intermediates therefor | TANABE SEIYAKU CO (JP) | 2001-03-28 | — | — | CN | disclosed |
| CN-1142497-A | Naphthalene derivatives, process for preparation thereof, and intermediates therefor | TANABE SEIYAKU CO (JP) | 1997-02-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176367-A1 | 1-Amino 1H-imidazoquinolines | IL2, IFNG, IL4I1 | KMT2A 2385/4885ALDH1A1 405/4885MAPT 3758/4885 |
| US-20050054640-A1 | 1-Amino 1H-imidazoquinolines | IL2, IFNG, IL4I1 | KMT2A 2385/4885ALDH1A1 405/4885MAPT 3758/4885 |
| US-20040192728-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | TRPV1, OPRL1, TRPV2 | KMT2A 2415/4885ALDH1A1 1216/4885MAPT 4519/4885 |
| US-20250090540-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | PIK3CA, PIK3CB, PIK3CD | KMT2A 2974/4885ALDH1A1 3698/4885MAPT 3881/4885 |
| US-20080300236-A1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | TRPV1, OPRL1, TRPV2 | KMT2A 2415/4885ALDH1A1 1216/4885MAPT 4519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.